549
Views
6
CrossRef citations to date
0
Altmetric
Drug Evaluation

Evaluating dasiglucagon as a treatment option for hypoglycemia in diabetes

, , , , , & show all
Pages 1311-1318 | Received 29 Dec 2019, Accepted 23 Mar 2020, Published online: 08 Apr 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Sagar Dholariya, Deepak Parchwani, Siddhartha Dutta & Ragini Singh. (2023) Clinical efficacy and safety of dasiglucagon in severe hypoglycemia associated with patients of type 1 diabetes mellitus: a systematic review and meta-analysis. Expert Review of Clinical Pharmacology 16:1, pages 61-71.
Read now
Yongjing Ju, Duzhen Zhang & Junyi Yang. (2022) Dasiglucagon for treating severe hypoglycemia in patients with diabetes. Expert Review of Clinical Pharmacology 15:7, pages 799-803.
Read now

Articles from other publishers (4)

Yahiya Y. Syed. (2022) Dasiglucagon in severe hypoglycemia: a profile of its use. Drugs & Therapy Perspectives 38:3, pages 105-111.
Crossref
Bo Xu, Gaorui Tang & Zhen Chen. (2021) Dasiglucagon: an effective medicine for severe hypoglycemia. European Journal of Clinical Pharmacology 77:12, pages 1783-1790.
Crossref
Diana Isaacs, Jennifer Clements, Neil Turco & Rachel Hartman. (2021) Glucagon: Its evolving role in the management of hypoglycemia. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 41:7, pages 623-633.
Crossref
Hannah A. Blair. (2021) Dasiglucagon: First Approval. Drugs 81:9, pages 1115-1120.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.